Gene Therapy for Spinal Muscular Atrophy approved by FDA

Gene Therapy for Spinal Muscular Atrophy approved by FDA

A new treatment for a rare childhood disorder which cost $2.125 million for a single dose, one of the most expensive medicine available is approved by The US Food and Drug Administration. Spinal Muscular Atrophy, a condition driven by defects in the SMN1 gene causing burdened babies lose muscle control, the medicine is designed to treat the disease. In the US each year about 400 babies is being affected by the illness and kills those with the most common type of the disease in a couple of years. The gene…

Read More